---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-24-000033"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:52:40.595405+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience Q2 2024 net loss $16.0M; cash $193.6M; Phase 2b MDD topline due Oct 2024

## Summary
- Cash, cash equivalents, and restricted cash of $193.6M as of June 30, 2024; expected to fund operations into 2027.
- Net loss of $16.0M for Q2 2024 vs $8.7M in Q2 2023; R&D expenses rose to $13.2M from $7.1M.
- Completed enrollment of 301 patients in Phase 2b MDD study of ALTO-100; topline data expected in October 2024.
- Initiated Phase 2 studies: ALTO-101 in schizophrenia CIAS, ALTO-203 in MDD with anhedonia, ALTO-100 in bipolar depression.
- Received $11.7M Wellcome Trust award for ALTO-100 in bipolar depression; added COO Michael Hanley.

## SEC filing metadata
- accession: 0001999480-24-000033
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000033/0001999480-24-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948024000033/alto-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-24-000033
- JSON: https://secwatch.observer/filing/0001999480-24-000033.json
- Plain text: https://secwatch.observer/filing/0001999480-24-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.